AgingResearch.NewsJoin free

Rapamycin analog

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Howard Hughes Medical Institute and 5 more
  • Model organisms1

Outcomes

1

mTOR signalling

downin human cells1downin yeast cells1

1 study

  1. Rapamycin analog inhibits mTOR signalling in human cells.

    “selective mTOR inhibition can be achieved in Saccharomyces cerevisiae and human cells”

    Cellswith mutant FKBP12 expression

    Tissue-restricted inhibition of mTOR using chemical genetics

    Proceedings of the National Academy of Sciences of the United States of America12 Sep 2022

  2. Rapamycin analog inhibits mTOR signalling in yeast cells.

    “selective mTOR inhibition can be achieved in Saccharomyces cerevisiae and human cells”

    Cellswith mutant FKBP12 expression

    Tissue-restricted inhibition of mTOR using chemical genetics

    Proceedings of the National Academy of Sciences of the United States of America12 Sep 2022

More on mTOR signalling

Latest

Related